|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||23.08 - 23.22|
|52 Week Range||19.25 - 23.23|
|PE Ratio (TTM)||213.89|
|Expense Ratio (net)||0.30%|
In 2Q17, AstraZeneca's Oncology segment reported revenues of $993 million, reflecting 19% growth at constant exchange rates compared to 2Q16.
GlaxoSmithKline’s (GSK) global pharmaceuticals business is a part of the pharmaceuticals segment. It reported revenues of 3.24 billion pounds during 2Q17.
Diabetes and Cardiovascular is one of Sanofi’s (SNY) most important business units, contributing over 20% of its pharmaceutical revenue. The franchise reported 10.7% revenue growth to 1.8 billion euros ...
In 1Q17, AstraZeneca’s (AZN) Brilinta reported total revenues of ~$224 million, which is 27% growth year-over-year on a constant currency basis.
Novartis’s research and development strategy is based on portfolio prioritization, introducing cost efficiencies, implementing breakthrough technologies, and introducing new management.